bluuebunny/crossref_metadata_2025_split huggingface dataset:
The cross-domain functional organization of posterior lateral temporal cortex: insights from ALE meta-analyses of 7 cognitive domains spanning 12,000 participants
Authors: Hodgson Victoria J , Lambon Ralph Matthew A , Jackson Rebecca L 
Published: October 2022

AbstractThe posterior lateral temporal cortex is implicated in many verbal, nonverbal, and social cognitive domains and processes. Yet without directly comparing these disparate domains, the region’s organization remains unclear; do distinct processes engage discrete subregions, or could different domains engage shared neural correlates and processes? Here, using activation likelihood estimation meta-analyses, the bilateral posterior lateral temporal cortex subregions engaged in 7 domains were directly compared. These domains comprised semantics, semantic control, phonology, biological motion, face processing, theory of mind, and representation of tools. Although phonology and biological motion were predominantly associated with distinct regions, other domains implicated overlapping areas, perhaps due to shared underlying processes. Theory of mind recruited regions implicated in semantic representation, tools engaged semantic control areas, and faces engaged subregions for biological motion and theory of mind. This cross-domain approach provides insight into how posterior lateral temporal cortex is organized and why.
Oral Presentation No. 03 Growth differentiation factor-15 and bleeding complication risk in patients with coronary artery disease, receiving combined antithrombotic therapy
Authors: Krivosheeva E , Komarov A , Dobrovolsky A , Titaeva E , Balakhonova T , Panchenko E 
Published: October 2022

Abstract

Introduction
Recent studies are aimed to find laboratory predictors of bleeding complications in patients receiving various regimens of antithrombotic therapy. One of these biomarkers is GDF-15.

Purpose
To study the significance of GDF-15 in relation to the development of bleeding outcomes in CAD patients with multifocal atherosclerosis, receiving combined antithrombotic therapy.

Methods
The data was obtained from the prospective registry REGATA-1 (NCT04347200). 122 patients (90 males), median age 69 [IQR 64; 76] yrs) with CAD and peripheral atherosclerosis of at least one vascular territory (≥ 50%), were enrolled. Half of the patients (47.5%) with sinus rhythm received acetylsalicylic acid in combination with rivaroxaban 2.5 mg bid. Other patients (52.5%) with concomitant atrial fibrillation received direct oral anticoagulants in combination with antiplatelet therapy after elective PCI. Median follow-up was 10 months [IQR 7.0;12.0]. The safety end point was BARC 2–5 bleedings. Plasma samples for GDF-15 identification were taken at the inclusion and analyzed using ELISA.

Results
Frequency of BARC 2–5 bleedings was 14%. Median GDF-15 level was 1248.5 pg/ml [947.8; 1791.0]. According to the quartile analysis, GDF-15 values in the top three quartiles of the distribution (cut-off value &gt; 948 pg/ml) were associated with higher frequency of bleeding events: 3.1% versus 17.8%, P = 0.0411. Bleeding-free survival in groups, formed depending on the level of GDF-15 (948 &gt; and ≤ 948 pg/ml), was 96.7% vs. 82.2%, respectively, Log-Rank P = 0.0408.

Conclusions
Increase in GDF-15 level (&gt; 948 pg/ml) is associated with the development of BARC 2-5 bleedings in CAD patients with multifocal atherosclerosis, receiving combined antithrombotic therapy.
Oral Presentation No. 41 High plasma von Willebrand factor concentration is associated with the development of bleeding complications in patients with polyvascular disease receiving multicomponent antithrombotic therapy
Authors: Krivosheeva E , Komarov A , Dobrovolsky A , Korobkova V , Titaeva E , Tripoten M , Balakhonova T , Panchenko E 
Published: October 2022

Abstract

Background
von Willebrand factor (VWF) is well known biochemical marker of endothelial dysfunction that increased may be associated with the development of thrombotic complications in patients with polyvascular disease (PD). We aimed to asses the relation of VWF to the development of bleeding outcomes in patients with PD receiving multicomponent antithrombotic therapy (MAT).

Material and methods
The data were obtained during the prospective register REGATA-1, NCT04347200. 95 patients (70 males), median age 67 [IQR 61; 72] with PD (coronary artery disease and peripheral atherosclerosis of at least one vascular territory ≥ 50%) were enrolled. 61% of patients received acetylsalicylic acid in combination with rivaroxaban 2.5 mg bid, other (39%)with clopidogrel. Median follow-up was 10 months [IQR 8.0; 12.0]. The safety end point was major and clinically relevant bleedings (type 2–5) according to the BARC classification. Plasma samples for VWF were taken at the inclusion and analyzed using ELISA.

Results
Frequency of BARC 2–5 bleedings was 20%. The most frequent (79%) was gastrointestinal bleedings. Median VWF plasma concentration was 154% [116; 196]. According to the quartile analysis, VWF values in the top three quartiles distribution (cut-off value &gt; 122%) were associated with a higher frequency of bleeding events: 3.7% versus 36.7%, OR 8.8; CI 1,11-69,9, ? = 0.0392. Bleeding-free survival in groups formed depending on the VFW plasma concentration (122 &gt; and ≤ 122%) was 96.2% vs. 73.9%, respectively, Log-Rank P = 0.0488.

Conclusions
Increase of VWF plasma concentration (&gt; 122%) is associated with the development of major and clinically relevant bleedings in patients with PD receiving MAT.
Oral Presentation No. 56 Elevated White Blood Cells Count and C-Reactive Protein as markers for coronary heart disease prognosis
Authors: Sá Débora , Mendonça Maria Isabel , Santos Marina , Temtem Margarida , Sousa Ana Célia , Rodrigues Mariana , Henriques Eva , Freitas Sónia , Borges Sofia , Ornelas Ilídio , Drumond António , Dos Reis Roberto Palma 
Published: October 2022

Abstract

Background
White blood count (WBC) and C-reactive protein (CRP) elevation are well-recognized inflammation indicators and considered risk factors for coronary heart disease (CHD). Most of the other newly introduced inflammatory risk markers are expensive to test, are not readily available, lack standardization, and have not been confirmed by multiple prospective studies. Whether these classic inflammatory markers may predict majoradverse coronary events (MACE) in CHD patients is controversial. We aimed to evaluate whether high WBC and CRP are independent risk factors for MACE occurrence in CHD patients with an extended follow-up.

Material and methods
A cohort of 1,713 CHD patients (mean age 54.0 ± 7.5 years, 78.6% male) was prospectively followed during an extended time of 4.9 ± 3.4 years (range 1 to 17 years). Bivariate and multivariate Cox regression with WBC, CRP and traditional risk factors (age,gender, smoking, family history, dyslipidemia, diabetesand BMI) analyzed those significantlyassociated with MACE.

Results and conclusions
MACE group presented a higher percentage of non-smokers (P = 0.006); hypertension (P = 0.003); dyslipidemia (P = 0.025) and diabetes (P &lt; 0.0001). WBC (P = 0.048) and CRP (P &lt; 0.0001) were also significantly higher in patients with MACE relatively to non-MACE patients. After multivariate Cox analysis, WBC and CRP remained significant risk factors for MACE, with diabetes and hypertension presenting as strong statistical value. As a conclution, the inflammatory CRP and WBC factors are accurate to predict MACE in secondary prevention. These biomarkersare easily accessed, providing helpful information in the prognosis of cardiovascular patients.
Oral Presentation No. 64 Elevated soluble glycoprotein VI, a specific predictor of bleeding risk in patients with chronic coronary syndromes undergoing percutaneous coronary intervention
Authors: Lahu* Shqipdona , Adler* Kristin , Ndrepepa Gjin , Mayer Katharina , Hein-Rothweiler Ralph , Bernlochner Isabell , Laugwitz Karl-Ludwig , Kastrati Adnan , Gawaz Meinrad , Massberg Steffen , Münch Götz 
Published: October 2022

Abstract

Background
Whether plasma levels of soluble glycoprotein VI (sGPVI) are able to predict ischemic or bleeding risk in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) is not known. The objective of this study was to answer this question.

Material and methods
The present study included 317 patients out of 334 patients of the ISAR-PLASTER trial (randomized trial of 2 doses of revacept vs. placebo), who underwent PCI for CCS and had baseline plasma sGPVI levels available. Patients were categorized into three groups according to tertiles of sGPVI: low (n = 106; sGPVI ≤ 9.5 ng/ml), intermediate (n = 106; sGPVI ≤ 16.2 ng/ml) and high tertile of sGPVI (n = 105; sGPVI ≥ 16.5 ng/ml). The composite of death and myocardial injury (MI) at 48 hours after randomization served as a measure of ischemic risk, and Bleeding Academic Research Consortium (BARC) type 1 to 5 bleeding at 30 days as a measure of bleeding risk.

Results and conclusions
Baseline plasma levels of sGPVI (before PCI and revacept administration) correlated with bleeding (bleeding incidence among low, intermediate and high sGPVI tertile: 11.8%, 13.6%, and 25.8%, respectively; P = 0.005), but not with ischemic events (incidence of death/MI among low, intermediate and high sGPVI tertile: 25.0%, 21.9%, and 26.9%, respectively; P = 0.70). Revacept did not interact with these associations. Elevated plasma sGPVI levels are associated with an increased risk of bleeding but not ischemic complications after PCI in patients with CCS.

Funding
German Center for Cardiovascular Research, Deutsches Herzzentrum München, Federal Ministry of Education and Research, and advanceCOR.
Oral Presentation No. 67 Thrombotic Events in COVID-19 Patients Admitted at Chinese General Hospital and Medical Center
Authors: Santos Joel , Beltran Jenny 
Published: October 2022

Abstract

Background
Thrombosis is among the most prominent and concerning complications associated with COVID-19. These thrombotic events have been associated in progression of ARDS and morbidity and mortality.

Methodology
Retrospective cohort study of 203 patients ≥ 18 years old with confirmed COVID-19 admitted on tertiary referal hospital from January to December 2021. All thrombotic events were established by clinical signs and symptoms, ultrasonography and CT scan.

Results and conclusions
Sixty five (32%) patients out of 203 developed thrombotic complications. The most common thrombotic event was pulmonary embolism (36%), followed by myocardial infarction (28%), cerebrovascular infarct (27%), DVT (25%), acute limb ischemia (7%) and lastly, mesenteric ischemia (6%). There were significant differences in demographic and clinical profile among COVID-19 patients with and without thrombotic events. Thrombosis was more commonly seen in advanced age (≥ 75 years, 49.2% vs. 23.9%; RR2.06, CI1.4–3.03), severe infection (severe, 24.6% vs. 19.6%; RR1.2, CI0.8–1.9 and critical and 47.7% vs. 10.1%; RR3.2, CI2.2–4.6, respectively), ICU admission (20% vs. 3.6%; RR2.6, CI1.8–3.7). Other complications were acute respiratory syndrome (83% vs. 43.5%; RR3.8, CI2.1–6.9), acute kidney injury (50.8% vs. 19.6%; RR2.46, CI1.68–3.6), major bleeding (9.2% vs. 0%; RR2.07, CI1.83–2.34), clinically relevant non-major bleeding (30.8% vs. 10.1%; RR2.21, CI1.52–3.22), hospitalization &gt; 21 days (29.2% vs. 13%; RR1.85, CI1.24–2,76), and all-cause mortality (60% vs. 3.6%; RR5.42, CI3.76–7.82). Patients who developed thrombosis had prolonged duration of immobilization, higher Padua prediction and CURB 65 scores, with wall motion abnormality in 2D-echocardiography, elevated D-dimer and pro-BNP, reduced oxygen saturation an often received invasive and non-invasive ventilation and hemoperfusion. Majority of patients was given thromboprophylaxis in both groups; hence a significant difference was not found. An institutional thromboprophylaxis protocol is needed in managing COVID-19 patients at risk for thrombotic events.
Poster No. 027 Clinical, echocardiographic, analytic and anatomical parameters: which are the main prognostic factors in hospitalized patients with acute pulmonary embolism?
Authors: Duarte Fabiana , Inês Barradas M , Oliveira Luís , Dos Santos Inês Coutinho , Machado Carina , Dourado Raquel , Martins Dinis 
Published: October 2022

Abstract

Background
Acute pulmonary embolism (PE) is a life-threatening disease and an early diagnosis and herapy are crucial. Several parameters for risk stratification have been evaluated and it's important to assess their impact on clinical practice.

Objective
We assessed four different parameters (clinical, echocardiographic, analytical and anatomical imaging parameters) - PESI class; PESI-Echo score; lactate and troponin I values and central or peripheral thrombi location. We determined a composite outcome of adverse events: shock, acute ventilatory failure, severe bleeding events or in-hospital mortality.

Methods
Retrospective single center analysis including 131 patients admitted for PE.

Results
Mean age of 67.6 ± 15.3 years-old and 71% patients were female. Eighty patients (63.4%) had arterial hypertension, 27.4% had a recent hospitalization or surgery and 16% an active neoplasm disease. According to the PESI classification, 29.8% of the patients were in class V, 26.7% in class III and 17.6% in class II. This classification had a weak positive correlation with the outcome (P &lt; 0.001; r = 0.37) as PESI-Echo score (p 0.018; r = 0.36). The majority (72.2%) of the in-hospital adverse events occurred in PESI class V patients. Analytic parameters determined at hospital admission had a good discriminative power to predict the outcome, mainly lactate value (AUC 0.864; P &lt; 0.001). PESI-Echo score presented the best discriminative power (AUC 1.0), followed by PESI class (AUC 0.925) and lactate (AUC 0.856). The cut-off value for PESI-Echo was 211.

Conclusion
The association of clinical and echocardiographic parameters was superior as a predictor of adverse events when compared with their isolated use.
Poster No. 054 Genetic variation in the TCF21 gene is associated with the severity of coronary artery disease
Authors: Sá Débora , Mendonça M I , Santos M , Temtem M , Sousa A C , Rodrigues M , Henriques E , Freitas S , Borges S , Guerra G , Freitas A I , Ornelas I , Drumond A , Palma Dos Reis R 
Published: October 2022

Abstract

Introduction
In vitro studies demonstrated that targeted deletion of the transcription factor encoding gene TCF21, was associated with vascular smooth muscle cell disruption. Recent research showed that TCF21 expression contribute to fibrous cap formation, preventing heart attacks.

Purpose
Analyse the TCF21 rs12190287 gene and evaluate its association with atherosclerosis severity measured according to the coronary angiogram patients´ data. Methods: Prospective study with 1,639 coronary artery disease (CAD) patients (mean age 53.4 ± 7.8 years). Two age groups (&lt; 55 and &gt; 55 years) were stratified and analyzed. TCF21 rs12190287 G &gt; C was genotyped in all patients. The severity of CAD was graded according to the number of obstructed coronary arteries with at least 70% narrowed lumen. Chi-squared tests and multivariate logistic regression models were analysed.

Results
The CC genotype was associated with &gt; 70% obstructive lesions (vascular disease rate, 48.1%). Contrariwise, the GG wild genotype was associated with less severe obstructive disease (19.5%) (P = 0.003). When we stratified the TCF21 genotypes per age group (55 years), the CC genotype in the younger group had more obstructed disease (47.4%) when compared with GG (18.8%) (P = 0.012), but this effect was not significant in the older group. Multivariate analysis (logistic regression) showed that the CC genotype had a high risk of multivessel coronary disease (OR = 2.88; P = 0.001) than GG.

Conclusion
This work shows that the TCF21 wild genotype protects against CAD severity. In contrast, the CC genotype is associated with an increased risk of CAD severity.
Oral Presentation No. 114 Small-bore aspiration thrombectomy versus catheter-directed thrombolysis in intermediate-high risk acute Pulmonary Embolism
Authors: Martinho Mariana , Calé Rita , Pereira Ana Rita , Ferreira Filipa , Alegria Sofia , Morgado Gonçalo , Martins Cristina , Ferreira Melanie , Gomes Ana , Judas Tiago , Gonzalez Filipe , Lohmann Corinna , Repolho Débora , Santos Pedro , Pereira Ernesto , Loureiro Maria José , Pereira Hélder 
Published: October 2022

Abstract

Introduction
Catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) are treatment options in intermediate-high risk pulmonary embolism (IHRPE).

Purpose
Compare the efficacy and safety of CDT and MT in IHRPE.

Methods
Retrospective single-centre study of consecutive IHRPE patients (pts) since 2018, treated with CDT (5Fr Cragg-McNamara device) or MT (Indigo MT system, Penumbra 8Fr). Clinical success at 48h was defined as survival and haemodynamic (HD) stabilization, oxygenation improvement or decrease in pulmonary hypertension (PH)/right heart strain. MACE during follow-up (FUP) was a composite endpoint of cardiovascular mortality, PE recurrence, chronic thromboembolic PH and heart failure hospitalization. Safety endpoint was defined as Major bleeding (BARC3).

Results
Of 25 pts, 60% were submitted to MT and 40% to CDT. Age (68.6 ± 15.6 vs. 62.7 ± 16.4, P = 0.381), Charlson Comorbidity Index (4.2 ± 1.9 vs. 2.9 ± 2.0, P = 0.121) and PESI score (103.2 ± 40.6 vs. 119.8 ± 46.2, P = 0.410) were similar. MT had increased fluoroscopy time (43.0 ± 19.1 vs. 10.1 ± 6.2 min, P &lt; 0.001) and procedure time (115 ± 63 vs. 45 ± 18 min, P = 0.009). Success at 48 h was similar (80% MT vs. 90% CDT; P = 0.626). Severe adverse events related with the technique happened in 2 pts in MT (1 death, 1 macroembolization) and 1pt in CDT developed HD instability. Haemoglobin fall was higher in MT (1.8 ± 1.3 vs. 0.7 ± 0.8 g/dL, P = 0.018), but BARC3 and transfusion were identical. In-hospital mortality was 8% (2 pts in MT, P = 0.229). Mean FUP was 229 ± 147days, with higher MACE in MT (40% vs. 0%, P = 0.051).

Conclusions
Despite similar efficacy at short-term, adverse events related to the procedure seemed higher in MT group. CDT was less time consuming.
Poster No. 115 Switch the risk: from PDE5i to Riociguat in real world pulmonary hypertension
Authors: Martinho Mariana , Alegria Sofia , Ferreira Filipa , Calé Rita , Repolho Débora , Pereira Ana Rita , Briosa Alexandra , Santos João Grade , Ferreira Bárbara , Cunha Diogo Santos , Baltazar Oliveira , Ilchyshyn Nazar , Luz João Mirinha , Loureiro Maria José , Pereira Hélder 
Published: October 2022

Abstract

Introduction
Switching from phosphodiesterase-5 inhibitors (PDE5i) to Riociguat is associated with increased efficacy in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Objective
To show clinical efficacy of replacing PDE5i to Riociguat in a portuguese PH-dedicated centre.

Methods
Retrospective single-centre study of PAH and inoperable/persistent/recurrent CTEPH patients (pts) who switched vasodilator therapy. Parameters were stratified according to the 2022 PH guidelines and stratification as low/intermediate/high-risk PH followed the COMPERA registry, before switching, at 3–6 months of follow-up (FUP) and until the last clinical evaluation, balloon pulmonary angioplasty (BPA), heart transplant or death.

Results
Of 13 pts, 75.0% had CTEPH (4 pts had persistent disease after surgical endarterectomy), 16.7% had PAH and 1pt had mixed PAH/CTEPH. Mean age was 56.2 ± 16.3years and 83.3% were females. Mean time until switch was 33.5 ± 25.5 months. Previous therapy was: 33.3% Sildenafil, 41.7% Sildenafil/Bosentan and 25% Sildenafil/Bosentan/prostanoid. Before switching, 66.7% had intermediate and 33.3% low-risk PH; at a FUP of 4.4 ± 1.7 months, 8.3% had intermediate and 91.7% low-risk PH. There was a significant benefit in the COMPERA risk (1.50[1.33;1.62] vs. 1.22[1.09;1.40], P = 0.011). Long-term FUP was performed in 8 pts at 48.2 ± 35.6 months (death 1pt, transplant 1pt, BPA 3 pts). Medical treatment was Riociguat in 33.3%, Riociguat and Bosentan in 58.3%, and 1pt with Riociguat, Bosentan and Treprostinil. Clinical benefit was significant at long-term FUP when compared to the initial evaluation (1.22[1.09;1.40], P = 0.011), but not to the first FUP.

Conclusion
This study corroborates previous evidence regarding the vasodilator switch and also suggests that the treatment goal is maintained throughout long-term FUP.
Poster No. 116 Hemodynamic characteristics associated with partial thrombosis of the false lumen in patients with chronic aortic dissection of the descending aorta: a 4D flow CMR study
Authors: Muñoz Aroa Ruiz , Guala Andrea , Dux-Santoy Lydia , Teixidó-Turà Gisela , Garrido-Oliver Juan , Garcia-Duran Ana , Valente Filipa , Galian-Gay Laura , Gutierrez Laura , Cuellar-Calabria Hug , Johnson Kevin , Wieven Oliver , Ferreira-Gonzalez Ignacio , Evangelista Arturo , Rodriguez-Palomares Jose 
Published: October 2022

Abstract

Background
Partial thrombosis of the false lumen (FL) in patients with chronic aortic dissection (AD) of the descending aorta has been associated with faster aortic dilation. Four-dimensional phase-contrast cardiovascular magnetic resonance (4D flow CMR) studies analyzing flow dynamics and biomechanics in the FL and their relationship with partial thrombosis are lacking. This study aimed to compare FL flow dynamics and biomechanics between patients with a patent and partially thrombosed FL.

Materials and methods
Patients with a chronic, patent (no thrombus) or partially thrombosed FL in the descending aorta after an AD underwent an imaging follow-up including a magnetic resonance angiography (MRA) and a 4D flow CMR study. FL thrombosis was quantified as the ratio of thrombus volume and FL volume on MRA. FL flow dynamics was assessed in terms of forward flow, wall shear stress (WSS), maximum kinetic energy (KE) and acceleration, and flow stasis on 4D flow CMR. Aortic stiffness in the FL was quantified using pulse wave velocity (PWV).

Results and conclusions
Sixty-five patients with a complete imaging protocol were included in the study (patency in 34 patients, partial thrombosis in 31). Partial thrombosis of the FL was associated with a reduction in the amount and energy of flow in the FL (reduced forward systolic flow, KE and acceleration), and a more stagnated flow in the FL (increased flow stasis). Axial WSS showed a tendency to be lower in the partial thrombosis group compared to the patency group, while PWV were similar in both of them.

Funding
IJC2018-037349-I.